Related Experiment Video
Updated: Jun 18, 2026
28:15
Deficient Pms2, ERCC1, Ku86, CcOI in Field Defects During Progression to Colon Cancer
Published on: July 28, 2010
Diagnosing xeroderma pigmentosum group C by immunohistochemistry
Sébastien de Feraudy1, Imenne Boubakour-Azzouz, Sylvie Fraitag
1Department of Dermatology, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, USA.
The American Journal of Dermatopathology
|November 17, 2009
Summary
Xeroderma pigmentosum group C (XPC) can be diagnosed using immunohistochemistry (IHC) on skin biopsies. This fast, inexpensive IHC method detects the absence of XPC protein in patients, offering a robust diagnostic alternative.
Area of Science:
- Genetics
- Dermatology
- Oncology
Background:
- Xeroderma pigmentosum (XP) comprises rare inherited neurocutaneous diseases.
- XP group C (XPC) is prevalent in the Americas and Europe.
- Current XP diagnostics involve complex, costly, and time-intensive assays.
Purpose of the Study:
- To evaluate immunohistochemistry (IHC) as a reliable diagnostic method for XPC.
- To assess the feasibility of using paraffin-embedded skin biopsies for XPC diagnosis.
Main Methods:
- Immunohistochemistry (IHC) staining for XPC protein.
- Analysis of 69 archived skin biopsy blocks from XP patients and controls.
- Comparison of XPC expression in healthy skin, XP-affected skin, and tumors.
Main Results:
- XPC protein expression was absent in all confirmed XPC patient biopsies (29/29).
- Strong XPC expression was observed in healthy skin and non-XPC XP patient biopsies (18/18).
- XPC signal persisted in sun-damaged areas and tumors in XPC patients.
Conclusions:
- IHC is a robust, fast, and inexpensive alternative for diagnosing XPC.
- Diagnosis can be made from non-sun-damaged skin biopsies.
- This IHC method holds potential for diagnosing other XP complementation groups.
